BeijngFH Health Cohort Study

Sponsor
Beijing Friendship Hospital
Study ID
NCT05546086
Status
Recruiting
Apply to this trial

Conditions

  • Non-Alcoholic Fatty Liver Disease

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

Metabolic associated fatty liver disease(MEFLD) is a major chronic liver disease that can lead to various adverse events, such as liver cancer, cardiovascular disease, and chronic kidney disease. The present community-based cohort study enrolls subjects who take health physical examinations at the sub-center outpatient department, Beijing Friendship Hospital. Investigators collect their baseline information, including demographic data, clinical history, physical examination, laboratory results, imageological examination, and so on. Follow-up surveys are conducted annually and the information collected is the same as the baseline. The outcome information, including cardiovascular disease, malignancy, liver cirrhosis, liver decompensation, liver transplantation, and all-cause mortality, are obtained by linking to the hospital discharge database and death registration system of Beijing. The primary aim of the study is to build a risk-stratified evaluation system for MAFLD through the cohort.

Key Dates

First listed
Sep 19, 2022
Start date
Apr 18, 2022
Status verified
Sep 2022
Primary completion
Apr 18, 2032
Completion
Apr 18, 2032

Study Design

Enrollment
8,103 participants (estimated)

Primary Outcome Measure

Cardiovascular disease [ Time Frame: 1 to 10 years ]

Central Contacts

Related Studies